Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

Multiplex Collagen Fingerprinting for the Staging of Hepatic Fibrosis Using High-Precision Fluorescence-Guided SERS Imaging

Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum

Serological Diagnosis Of Liver Fibrosis By Quantitative Estimation Of Serum Biomarkers Using Luminex Xmap Assay

3D-Printed SERS Chips for Highly Specific Detection of Denatured Type I and IV Collagens in Blood for Early Hepatic Fibrosis Diagnosis

Detection of fibrotic changes in the progression of liver diseases by label‐free multiphoton imaging

Dynamic Monitoring of the Fibrosis Disease by a Collagen Targeting Near Infrared Probe.

Dynamic monitoring the fibrosis disease by collagen targeting near infrared probe

Label-free characterization of pathological changes in the portal area of liver fibrosis tissue using multiphoton imaging and quantitative image analysis

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Nonlinear Optical Microscopy: Use of Second Harmonic Generation and Two-Photon Microscopy for Automated Quantitative Liver Fibrosis Studies

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

Damaged collagen detected by collagen hybridizing peptide as efficient diagnosis marker for early hepatic fibrosis

A novel alternative strategy for monitoring and insight into liver fibrosis progression: The combination of surface-enhanced Raman spectroscopy (SERS) and gut microbiota

Simultaneous Fingerprinting of Multiplex Collagen Biomarkers in Connective Tissues by Multicolor Quantum Dots-Based Peptide Probes

Stage scoring of liver fibrosis using Mueller matrix microscope

Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis

Quantitative assessment of hepatic steatosis using label-free multiphoton imaging and customized image processing program

Multiplexed Imaging Mass Spectrometry of Histological Staining, N-Glycan and Extracellular Matrix from One Tissue Section: A Tool for Fibrosis Research

Ultrasensitive, Multiplex Raman Frequency Shift Immunoassay of Liver Cancer Biomarkers in Physiological Media.

The Detection and Clinical Application of Serologic Biomarkers for Liver Fibrosis, the Present and Future Perspectives

Simultaneous Detection of Multiplex Biomarkers Related with Hepatocellular Carcinoma by Coupling DNase I-Assisted Recycling Amplification and Microfluidic Electrokinetic Stacking Chip with Parallel Multi-Channels